Home Cart Sign in  
Chemical Structure| 1675203-84-5 Chemical Structure| 1675203-84-5

Structure of BMS-202
CAS No.: 1675203-84-5

Chemical Structure| 1675203-84-5

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

BMS-202 is an effective non-peptide PD-1/PD-L1 complex inhibitor with an IC50 of 18 nM and a KD of 8 μM. BMS-202 has antitumor activity by directly binding to PD-L1 and blocking the interaction between human PD-1 and PD-L1.

Synonyms: Programmed Cell Death 1/Programmed Cell Death-Ligand 1 Inhibitor 2; PD-1/PD-L1 inhibitor 2

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of BMS-202

CAS No. :1675203-84-5
Formula : C25H29N3O3
M.W : 419.52
SMILES Code : CC(NCCNCC1=CC=C(OCC2=C(C)C(C3=CC=CC=C3)=CC=C2)N=C1OC)=O
Synonyms :
Programmed Cell Death 1/Programmed Cell Death-Ligand 1 Inhibitor 2; PD-1/PD-L1 inhibitor 2
MDL No. :MFCD29905455
InChI Key :JEDPSOYOYVELLZ-UHFFFAOYSA-N
Pubchem ID :117951478

Safety of BMS-202

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

Description
BMS-202 is identified as a potent and nonpeptidic inhibitor of the PD-1/PD-L1 complex, demonstrating an IC50 of 18 nM and a KD of 8 μM. It binds to PD-L1, effectively preventing the interaction between human PD-1 and PD-L1, and exhibits antitumor capabilities[1].[2].
Target
  • PD-1/PD-L1 interaction

    PD-1/PD-L1 interaction, IC50:0.018 μM

In Vitro:

Cell Line
Concentration Treated Time Description References
4T1 cells 1 µg/mL 30 minutes To evaluate the uptake of PEI-FA@IR@TPZ/BMS LPs in 4T1 cells, the results showed that the fluorescence intensity increased over time, indicating increased cellular uptake. PMC11391708
A2780 cells 1 µg/mL 2 hours To evaluate the uptake of FA-modified liposomes in A2780 cells, the results showed that FA-modified liposomes significantly increased uptake in A2780 cells. PMC11391708
bEND.3 cells 1 µg/mL 2 hours To evaluate the uptake of FA-modified liposomes in bEND.3 cells, the results showed no significant difference in uptake of FA-modified liposomes in bEND.3 cells. PMC11391708
U251 cells 10 μM 24 hours Assess the antitumor activity of BMS-202, results showed significantly reduced cell viability PMC10912212
LN229 cells 10 μM 24 hours Assess the antitumor activity of BMS-202, results showed significantly reduced cell viability PMC10912212
HEB cells 10 μM 24 hours Assess the antitumor activity of BMS-202, results showed no significant effect on cell viability PMC10912212
U251 cells 25 μM 24 hours Assess the effect of BMS-202 on cell migration, results showed significantly suppressed cell migration PMC10912212
L929 cells 1.56-50.00 μg/ml 24 hours Evaluate the cytotoxicity of nanocomplexes, results showed that in the concentration range of 1.56-50.00 μg/ml, the viability of L929 cells remained almost unchanged, indicating good cytocompatibility PMC10668380
4T1 cells 1.56-50.00 μg/ml 24 hours Evaluate the cytotoxicity of nanocomplexes on cancer cells, results showed that under 660 nm laser irradiation, the viability of 4T1 cells significantly decreased, indicating effective induction of cell death by photodynamic therapy PMC10668380
RM-1 cells 15 μg/mL 180 seconds Detect the ROS generated by YBS NPs-RKC under NIR laser irradiation, confirming its outstanding ROS production ability PMC10558672
RM-1 cells 15 μg/mL 150 seconds Detect the 1O2 generated by YBS NPs-RKC under NIR laser irradiation, confirming its outstanding ROS production ability PMC10558672
4T1 cells 10 µM 12 hours To observe the cellular endocytosis of nanomaterials, the results showed that BMS@Pt2Au4 NPs were more easily engulfed by 4T1 cells. PMC11657501
4T1 cells 10 µg/mL 12 hours To detect intracellular O2 levels, the results showed that Pt2Au4 NCs and BMS@Pt2Au4 NPs could catalyze H2O2 to generate O2, reducing the red fluorescence intensity of [Ru(dpp)3]Cl2. PMC11657501

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
BALB/C mice 4T1 breast cancer model Tail vein injection 10 mg/kg Once daily for 21 days To evaluate the anti-tumor effect of PEI-FA@IR@TPZ/BMS LPs in the 4T1 breast cancer model, the results showed that PEI-FA@IR@TPZ/BMS LPs significantly inhibited tumor growth and promoted tumor cell apoptosis. PMC11391708
NOD/SCID nude mice U251-bearing nude mice xenografts Intraperitoneal injection 1 mg/kg Once daily for seven days Assess the antitumor activity of BMS-202 in vivo, results showed significantly inhibited tumor growth PMC10912212
BALB/c mice 4T1 breast cancer model Tail vein injection 2 μmol/kg Once daily for 28 days Evaluate the in vivo therapeutic effect of BMS@P/HP on 4T1 tumors, results showed that under 660 nm laser irradiation, BMS@P/HP significantly inhibited tumor growth and induced immunogenic cell death, reshaping the tumor immune microenvironment PMC10668380
C57BL/6J mice RM-1 subcutaneous tumor model intravenous injection PCN-224 dose of 25 mg/kg, BMS-202 dose of 5 mg/kg Administered every two days for a total of three doses Evaluate the tumor suppression ability of YBS-BMS NPs-RKC under NIR laser irradiation, the results showed that it significantly inhibited tumor growth and prolonged the survival of mice PMC10558672
Mice 4T1 subcutaneous tumor model Intravenous injection 50mg/kg once daily for 4 weeks To evaluate the antitumor effect of BMS@Pt2Au4 NPs in vivo, the results showed that BMS@Pt2Au4 NPs combined with X-ray irradiation significantly inhibited tumor growth, with a tumor inhibition rate of 92.5%. PMC11657501

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.38mL

0.48mL

0.24mL

11.92mL

2.38mL

1.19mL

23.84mL

4.77mL

2.38mL

References

 

Historical Records

Categories